Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 4/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL19741548 | 1.00 | CA2 (0.45) | CA2CA4TDP1SMN1; SMN2MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL167682 | 1.00 | CA2 (0.45) | CA2CA4TDP1SMN1; SMN2MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL18528187 | 1.00 | CA2 (0.45) | CA2CA4TDP1SMN1; SMN2MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL163692 | 1.00 | CA2 (0.45) | CA2CA4TDP1SMN1; SMN2MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL10763594 | 0.97 | CA2 (0.44) | CA2CA4TDP1SMN1; SMN2MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL11297426 | 0.97 | CA2 (0.44) | CA2CA4TDP1SMN1; SMN2MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL6954583 | 0.97 | CA2 (0.44) | CA2CA4TDP1SMN1; SMN2MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL27949540 | 0.97 | CA2 (0.44) | CA2CA4TDP1SMN1; SMN2MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL28052876 | 0.95 | CA2 (0.42) | CA2CA4TDP1SMN1; SMN2MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL431199 | 0.91 | GLRA1 (0.43) | CA2CA4TDP1SMN1; SMN2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 38858 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121902886-B | Digital impulse neuron, impulse neural network and realization method thereof | 中国科学技术大学 | 2026-05-22 | — | — | CN | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026102000-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA 1 DEFICIENCY | VOYAGER THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260130871-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-14 | — | — | US | claimed |
| US-12622932-B2 | Immunomodulatory cells and uses thereof | SINAI HEALTH SYSTEM (CA) | 2026-05-12 | — | — | US | claimed |
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260118363-A1 | Application of GLUN2A and NMDA Receptor Containing GLUN2A as Targets in Screening Drugs for Treating Depression | SYNPHATEC SHANGHAI BIOPHARMACEUTICAL TECH CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-4888347-A | Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration | MERCK SHARP & DOHME LIMITED (GB) | 1989-12-19 | — | — | US | claimed |
| US-4870079-A | ANTICONVULSANTS, ANTAGONISTS OF N-METHYL-D-ASPARTATE | MERCK & CO., INC. (US) | 1989-09-26 | — | — | US | claimed |
| WO-1989007098-A1 | BUTYRL-TYROSINYL SPERMINE, ANALOGS THEREOF AND METHODS OF PREPARING AND USING SAME | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF (US) | 1989-08-10 | — | — | WO | claimed |
| EP-0324595-A2 | Amino-functional compounds as builders/dispersants in detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1989-07-19 | — | — | EP | claimed |
| WO-1989005641-A1 | DEXTROMETHORPHAN POTENTIATOR FOR ANTICONVULSANT COMPOSITION AND METHOD | PONTECORVO MICHAEL J (US) | 1989-06-29 | — | — | WO | claimed |
| EP-0303387-A1 | Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders | MERCK SHARP & DOHME LTD. (GB) | 1989-02-15 | — | — | EP | claimed |
| WO-1988007851-A1 | LIPOSOME ENTRAPPED N-METHYL-D-ASPARTATE RECEPTOR BLOCKERS | INNOVATIVE THERAPEUTICS CORPORATION (US) | 1988-10-20 | — | — | WO | claimed |
| WO-1988007811-A2 | TREATMENT OF TRAUMATIC INJURY WITH NMDA RECEPTOR BLOCKERS | INNOVATIVE THERAPEUTICS CORPORATION (US) | 1988-10-20 | — | — | WO | claimed |
| US-4746653-A | ANTAGONISTS OF N-METHYL-D-ASPARTATE SENSITIVE EXCITATORY AMINO ACID RECEPTOR; TREATMENT OF MUSCULAR SPASMS, CONVULSIVE DISORDERS AND ANXIETY | CIBA-GEIGY CORPORATION (US) | 1988-05-24 | — | — | US | claimed |
| EP-0203891-A2 | Certain phosphonic acids and derivatives | CIBA-GEIGY AG (CH) | 1986-12-03 | — | — | EP | claimed |